Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP800646.RA-jkOTdzUGqHJOZpEWhBPnL11lDdPoBwGch0RCviY9Ig130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP800646.RA-jkOTdzUGqHJOZpEWhBPnL11lDdPoBwGch0RCviY9Ig130_assertion type Assertion NP800646.RA-jkOTdzUGqHJOZpEWhBPnL11lDdPoBwGch0RCviY9Ig130_head.
- NP800646.RA-jkOTdzUGqHJOZpEWhBPnL11lDdPoBwGch0RCviY9Ig130_assertion description "[This specifically applies to children with severe congenital neutropenia who receive lifelong treatment with G-CSF and in which the high susceptibility to develop MDS and acute myeloid leukemia (AML) has now become a major clinical concern.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP800646.RA-jkOTdzUGqHJOZpEWhBPnL11lDdPoBwGch0RCviY9Ig130_provenance.
- NP800646.RA-jkOTdzUGqHJOZpEWhBPnL11lDdPoBwGch0RCviY9Ig130_assertion evidence source_evidence_literature NP800646.RA-jkOTdzUGqHJOZpEWhBPnL11lDdPoBwGch0RCviY9Ig130_provenance.
- NP800646.RA-jkOTdzUGqHJOZpEWhBPnL11lDdPoBwGch0RCviY9Ig130_assertion SIO_000772 20237318 NP800646.RA-jkOTdzUGqHJOZpEWhBPnL11lDdPoBwGch0RCviY9Ig130_provenance.
- NP800646.RA-jkOTdzUGqHJOZpEWhBPnL11lDdPoBwGch0RCviY9Ig130_assertion wasDerivedFrom befree-2016 NP800646.RA-jkOTdzUGqHJOZpEWhBPnL11lDdPoBwGch0RCviY9Ig130_provenance.
- NP800646.RA-jkOTdzUGqHJOZpEWhBPnL11lDdPoBwGch0RCviY9Ig130_assertion wasGeneratedBy ECO_0000203 NP800646.RA-jkOTdzUGqHJOZpEWhBPnL11lDdPoBwGch0RCviY9Ig130_provenance.